Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

qRT-PCR (real-time reverse transcription-PCR) has become the benchmark for the detection
and quantification of RNA targets and is being utilized increasingly in novel clinical …

Abstract Imatinib mesylate (IM), 400 mg daily, is the standard treatment of Philadelphia-
positive (Ph+) chronic myeloid leukemia (CML). Preclinical data and results of single-arm …

1Department of Hematology-Oncology" L. and A. Seràgnoli" University of Bologna, Bologna;
2Onco-Hematology Unit, University of Naples Federico II and CEINGE, Biotecnologie …

In chronic myeloid leukemia, different methods are available to monitor the response to
therapy: chromosome banding analysis (CBA), interphase fluorescence in situ hybridization …

Imatinib is the standard front-line therapy of chronic myeloid leukaemia (CML). The
evaluation of the response is based on blood counts and differential (haematologic …

The Ph1 chromosome has rarely been reported in T-lineage acute lymphoblastic leukemia
(T-ALL), and the clinical relevance of this translocation in T-ALL is currently unknown. In …

Chronic myeloid leukemia provides an illustrative disease model for both molecular
pathogenesis of cancer and rational drug therapy. Chronic myeloid leukemia is a clonal …

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase
chronic myeloid leukemia: a study of the Spanish PETHEMA group - PMC Back to Top Skip to …

The unique molecular characteristic of chronic myeloid leukemia (CML), the disease-
causing ABL (9q34) to BCR (22q11) translocation, has provided an invaluable tool for …